---
title: "This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277616187.md"
description: "Top Wall Street analysts have initiated coverage on several companies with positive outlooks. Stifel's James Condulis rated Amylyx Pharmaceuticals (AMLX) as Buy with a $21 target; shares closed at $15.30. Goldman Sachs' Leah Jordan rated Once Upon A Farm (OFRM) as Buy with a $43 target; shares closed at $23.58. Morgan Stanley's Judah Frommer rated Agomab Therapeutics (AGMB) as Overweight with a $28 target; shares closed at $16.21. Stifel's Tom Stephan rated SpyGlass Pharma (SGP) as Buy with a $42 target; shares closed at $26.73."
datetime: "2026-03-03T11:57:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277616187.md)
  - [en](https://longbridge.com/en/news/277616187.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277616187.md)
---

# This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Stifel analyst James Condulis initiated coverage on **Amylyx Pharmaceuticals Inc** (NASDAQ:AMLX) with a Buy rating and announced a price target of $21. Amylyx Pharmaceuticals shares closed at $15.30 on Monday. See how other analysts view this stock.
-   Goldman Sachs analyst Leah Jordan initiated coverage on **Once Upon A Farm PBC** (NYSE:OFRM) with a Buy rating and announced a price target of $43. Once Upon a Farm shares closed at $23.58 on Monday. See how other analysts view this stock.
-   Morgan Stanley analyst Judah Frommer initiated coverage on **Agomab Therapeutics NV** (NASDAQ:AGMB) with an Overweight rating and announced a price target of $28. AgomAb Therapeutics shares closed at $16.21 on Monday. See how other analysts view this stock.
-   Stifel analyst Tom Stephan initiated coverage on **SpyGlass Pharma, Inc.** (NASDAQ:SGP) with a Buy rating and announced a price target of $42. SpyGlass Pharma shares closed at $26.73 on Monday. See how other analysts view this stock.

Considering buying AMLX stock? Here’s what analysts think:

Photo via Shutterstock

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SGP.US](https://longbridge.com/en/quote/SGP.US.md)
- [AGMB.US](https://longbridge.com/en/quote/AGMB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [OFRM.US](https://longbridge.com/en/quote/OFRM.US.md)
- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday](https://longbridge.com/en/news/282051007.md)
- [Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | AMLX Stock News](https://longbridge.com/en/news/282261513.md)
- [AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance](https://longbridge.com/en/news/282227475.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)